//]]>
Normal View MARC View ISBD View

Cooley's anemia : ninth symposium /

Authors: Vichinsky, Elliott P.%editor | Neufeld, Ellis Jacob.%editor | New York Academy of Sciences. Series: Annals of the New York Academy of Sciences, 0077-8923 ; . 1078 Published by : WileyInterScience, (Hoboken, N.J :) Physical details: 267 p. : ill. (some col.) ISBN: 1573317829 Subject(s): Thalassemia | beta-Thalassemia Year: 2010
Online Resources:
Tags from this library:
No tags from this library for this title.
Item type Location Call Number Status Notes Date Due
Book Book AUM Main Library English Collections Hall 616.152 C774 (Browse Shelf) Available JBC/2011/11262
Book Book AUM Main Library English Collections Hall 616.152 C774 (Browse Shelf) Available JBC/2011/11262
Browsing AUM Main Library Shelves, Shelving Location: English Collections Hall Close Shelf Browser
Previous
Next
616.15 P168Haematology / 616.150758 T383Color atlas of hematology : 616.150758 T383Color atlas of hematology : 616.152 C774Cooley's anemia : 616.152 C774Cooley's anemia : 616.157 E87Essential guide to blood coagulation /

Title from resource title screen (WileyInterScience, viewed August 23, 2010)

Includes bibliographical references.

Clinical trials in thalassemia: insights from the patient community -- Pathogenesis and management of iron toxicity in thalassemia -- The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia -- Thalassemia as a global health problem: recent progress toward its control in the developing countries -- Iron metabolism and ineffective erythropoiesis in �-thalassemia mouse models -- Hepcidin in �-thalassemia -- Therapy for �-globinopathies: a brief review and determinants for successful and safe correction -- Humanized mouse models of Cooley's anemia: correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology -- Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in �-thalassemia -- Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease -- Transcriptional silencing of fetal hemoglobin by BCL11A -- The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in �-thalassemia patients -- Deferiprone -- Combined iron chelation therapy -- Deferasirox: current knowledge and future challenges -- Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron -- Critical appraisal of growth retardation and pubertal disturbances in thalassemia -- Magnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron -- Predicting pituitary iron and endocrine dysfunction -- Better survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature --

A preclinical approach for gene therapy of �-thalassemia -- The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation -- Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia -- Emerging insights in the management of hemoglobin E beta thalassemia -- Fetal globin gene inducers: novel agents and new potential -- Detection of the cardiovascular complications of thalassemia by echocardiography -- Cardiovascular MRI in thalassemia major -- Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy -- Nutritional deficiencies in patients with thalassemia -- Ferritin iron minerals are chelator targets, antioxidants, and coated, dietary iron -- Pulmonary hypertension in thalassemia -- The natural history of thalassemia intermedia -- Hepcidin and Hfe in iron overload in �-thalassemia -- Fertility potential in thalassemia major women: current findings and future diagnostic tools -- Redefining thalassemia as a hypercoagulable state -- Treatment options for thalassemia patients with osteoporosis -- Health care transition in thalassemia: pediatric to adult-oriented care -- Ninth Cooley's Anemia Symposium: summary and perspective.

"Thanks to scientific advances, individuals with thalassemi--a group of genetic blood disorders which includes Cooley's Anemia--are now living into their forties and fifties. Not only are individuals living longer, but their quality of life has increased. Scientific and clinical advancements have resulted in new iron-chelating drugs, early detection of organ failure, an understanding of adult complications associated with living with thalassemia (osteoporosis, heart failure, growth hormone deficiency, pulmonary hypertension, and infertility), and promising progress towards the ultimate magic bullet--a cure in the form of bone marrow and cord blood transplants, or gene therapy. The papers from this symposium integrate basic science and clinical research so that both scientists and clinicians can develop a mutual understanding of recent progress in thalassemia."--Society website.

There are no comments for this item.

Log in to your account to post a comment.

Languages: 
English |
العربية